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Psoriatic arthritis

Original article
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Abstract

Objective To compare the characteristics of patients
with psoriatic arthritis among patient groups stratified by
degree of skin and joint involvement, and to evaluate the
relationship between skin severity and joint activity.
Methods Body surface area (BSA) and Clinical Disease
Activity Index (CDAI) at enrolment were analysed. Patient
characteristics were stratified by skin severity and joint
activity. Baseline patient characteristics, clinical and
disease characteristics and patient-reported outcomes
►► Prepublication history for
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Introduction
Psoriatic arthritis (PsA) is a chronic,
inflammatory condition that presents with
cutaneous (involvement of skin and nails),
musculoskeletal
(arthritis,
enthesitis,

Key messages
What is already known about this subject?
►► Limited information is known about the relationships

between skin disease severity and joint disease activity in patients with psoriatic arthritis (PsA).
►► Studies examining the clinical characteristics of
patients with PsA have not found consistent correlations between baseline skin and joint disease
measures.

What does this study add?
►► Our study found the strength of the relationship be-

tween joint disease activity and skin disease severity
was modest, yet statistically significant.
►► Patients with higher skin disease severity (body surface area (BSA) >3%) were two times more likely
to have higher joint disease involvement compared
with those with a BSA=0%.

How might this impact on clinical practice?
►► Clinicians (specifically rheumatologists and der-

matologists) need to approach PsA patient care
comprehensively addressing both the skin disease
severity and joint disease activity in the treatment
of these patients.

dactylitis and spondylitis) and extra-articular features (inflammatory bowel disease,
uveitis).1–3 Psoriasis (PsO) affects up to
3.2% of the population in the USA, and
studies have found up to 30% of patients
with PsO have PsA.4 5 Compared with the
general population, patients with PsA have
a lower health-related quality of life (QOL)
and experience a higher risk of developing
comorbidities including malignancy and
cardiovascular disease. Previous studies of
patients with PsA have shown that patients
with skin involvement have a more significant impairment of QOL measures and an
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increase in overall comorbidities.6 7 Studies examining
the clinical characteristics of patients with PsA have
not found consistent correlations between baseline
skin and joint disease measures.8–11 Determining the
relationship between severity of skin disease and joint
disease activity is important for better phenotyping
of patients with both skin and joint involvement and
can guide clinicians in management. The objectives
of this study were to compare patient characteristics
(demographics, comorbidities, symptoms and medications) at enrolment among patient groups defined by
degree of skin and joint involvement, and to evaluate
the relationship between the degree of skin and joint
involvement.

Methods
Data source
The Corrona Registry is an independent, prospective, observational cohort of patients with PsA recruited at 40 private
and academic practice sites across 25 states in the USA.12 As of
31 March 2018, the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry database included information
on 2827 patients. Data on 11 525 patient visits and approximately 6278 patient-years of follow-up observation time had
been collected. The mean time of patient follow-up was 3.1
years (median, 3.5 years). Data were collected from both
patients and their treating rheumatologists, who gathered
information on disease duration, prognosis, disease severity
and activity, medical comorbidities, use of medications
including biologics, conventional synthetic disease-modifying antirheumatic drugs (csDMARD), prednisone and
adverse events. Follow-up assessments were requested at
least as often as every 6 months and completed during
routine clinical encounters. The Corrona Registry was
established in accordance with the Declaration of Helsinki.
All participating investigators were required to obtain full
board approval for conducting non-interventional research
involving human subjects. Sponsor approval and continuing
review were obtained through a central Institutional Review
Board (IRB). For academic investigative sites that did not
receive a waiver to use the central IRB, full board approval
was obtained from the respective governing IRBs and documentation of approval was submitted to Corrona before
initiating any study procedures. All registry patients were
required to provide written informed consent and authorisation before participating.
Study population
Our study cohort included 1542 patients in the Corrona
PsA/SpA Registry who were continuously enrolled
following an index date defined as enrolment between 21
March 2013 and 20 September 2016. Patients ≥18 years of
age with a diagnosis of PsA and with a history of PsO at the
time of enrolment into the Corrona PsA/SpA Registry were
recruited for the study. Patients were further required to
have available body surface area (BSA) and Clinical Disease
Activity Index (CDAI) measurements at enrolment. BSA is
2

usually measured by estimating the per cent body involvement of PsO, and it ranges from 0% to 100%. One per cent
BSA represents a one handprint size of the patient. The
CDAI was developed to determine a patient’ s joint disease
activity for rheumatoid arthritis but can also be used for
PsA.13 The CDAI comprised four assessment tools: swollen
(28) joint count, tender (28) joint count, Patient Global
disease Activity and the Evaluator’s Global disease Activity
indexes. A CDAI activity score of ≤2.8 is considered remission, a CDAI score >2.8 and ≤10 is low disease activity, a
CDAI score >10 and ≤22 is moderate disease activity and a
CDAI score >22 is high disease activity.14
For purposes of our study, patients with PsA were
stratified by skin disease severity and joint disease
activity determined at enrolment as follows: BSA 0%
(history of PsO but not current/active); low (BSA >0%
to ≤3%); and moderate-high (BSA >3%). Joint disease
activity was measured by CDAI, where a CDAI ≤10 was
low and a CDAI >10 was considered moderate-high.
Patients were further divided into six subgroups:
BSA 0%/CDAI low; BSA 0%/CDAI moderate-high;
BSA >0% to ≤3%/CDAI low; BSA >0% to ≤3%/CDAI
moderate-high; BSA >3%/CDAI low; and BSA >3%/
CDAI moderate-high. Demographic characteristics,
duration of PsA, time since PsO diagnosis, clinical
characteristics, patient-reported outcomes, history
of PsA drug therapy and current PsA drug therapy at
enrolment were also collected.
Statistical analyses
Comparison of baseline characteristics by skin disease severity
and joint disease activity
Patient characteristics, including current and prior PsA
medication use, were obtained during the enrolment visit
and stratified by skin disease severity and joint disease
activity. We compared baseline patient characteristics,
clinical and disease characteristics and patient-reported
factors among the six stratified skin disease severity-joint
disease activity groups using appropriate methods: analysis of variance for continuous variables and χ2 test of
association (for categorical variables; Fisher’s test used if
a cell count had <5). Any comparison with a resulting
p value <0.05 was flagged and considered in the list of
factors used for evaluating the relationship between skin
disease severity and joint disease activity.
Evaluating the relationship between skin disease severity and joint
disease activity and factors that modify the relationship
The overall relationship of skin disease severity evaluated
by BSA and joint disease activity (evaluated by CDAI)
levels was calculated using the χ2 test of association,
and the strength of the relationship between these two
variables was measured using Cramer’s V, which is the
standard correlation of two categorical variables with two
or more categories each. Cramer’s V is used in conjunction with a significant χ2 test to determine the strength of
association. Cramer’s V ranges from 0 (no relationship)
to 1 (strong relationship). Also, we calculated the OR
Mease PJ, et al. RMD Open 2019;5:e000867. doi:10.1136/rmdopen-2018-000867
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to estimate the risk of being in moderate or high joint
disease activity among patients with severe skin severity
compared with patients with low joint disease activity and
no skin involvement (BSA=0).
To further evaluate whether other variables (chosen a
priori or identified through significance testing) modified
the relationship between CDAI and BSA, multiple linear
regression was performed starting with the list of a priori variables (ie, age, gender, body mass index (BMI), work status,
smoking status, duration of PsA, time since PsO diagnosis,
prior biologic or targeted synthetic DMARD (tsDMARD)
use, current biologics or tsDMARD use, prior csDMARD
use, Spondyloarthritis Research Consortium of Canada
(SPARCC) enthesitis and dactylitis count and minimal
disease activity (MDA)), and each variable was included in
a separate model of CDAI regressed onto BSA. Effect modification of each variable was evaluated by including an interaction term (BSA and the variable under evaluation) into
the linear regression model and assessed for statistical significance with the likelihood ratio test p<0.05.

Results
There were 1542 patients who met the inclusion criteria.
The skin activity groups were categorised as follows:
24% (0% BSA), 44% (low BSA) and 32% of patients
had moderate/high BSA levels. The low CDAI group
comprised 62% of all patients (table 1).
All patient demographic characteristics
The preponderance of patients were (52.9%) females.
The mean age for all patients was 53.7 years, and most
patients in the study (94.4%) were white, and 52.8%
never smoked. More than 62% of all patients worked
part-time or full time, and 8.9% of all patients were disabled. Nearly 80% of all patients had private insurance of
some kind, and the mean BMI for all patients was 31.5
(±7.2). The median PsA duration since diagnosis was
9 years, and 18 years for PsO. Over 62% of all patients
reported a history of biologic use. For those patients
currently reporting DMARD therapy, 17.9% were not
on any DMARD therapy at enrolment, 29% were on
methotrexate or another csDMARD and 53.1% were on
biologics/tsDMARDs (table 1).
Patient demographic characteristics by degree of skin and
joint involvement
At the time of enrolment, within each BSA group,
higher BMIs were found among patients with higher
CDAI, and the highest BMI (33.1±7.7) was observed
in patients in the BSA >3%/CDAI medium-high
subgroup. Significant differences were observed for
current therapy among the six subgroups. Of note,
those patients in the BSA 0%/CDAI low subgroup for
skin disease severity and joint disease activity reported
the highest use of any drug therapy with 63.7% using
biologics/tsDMARDs (table 1).
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All patient disease characteristics and patient-reported
outcomes
Among all patients, 18.3% had enthesitis and a SPARCC
score >0. The mean SPARCC score for those with
enthesitis was 4.1±3.1. Nearly 45% of patients were in
MDA. The mean BSA was 5.6 (±11.2), and the mean
CDAI was 10.4 (±9.3). For the global assessment of PsO,
25% were clear, 35.5% were almost clear, 24.4% had mild
disease, 13.1% moderate disease and 2% severe disease.
For the Disease Activity Score 28-joint count C-reactive
protein, the majority of patients were in remission/low at
57.9%, 30.4% were moderate and 11.7% were considered
high. The mean Nail PsO visual analogue scale (VAS)
score was 7.2 (±16.5), and the mean Health Assessment
Questionnaire (HAQ) was 0.61 (±0.6). Patient-reported
pain was 37.6 (±29.3), and patient-reported fatigue was
40.2 (±29.1) (table 2).
Patient disease characteristics and patient-reported
outcomes by degree of skin and joint involvement
Patients in the BSA >3%/CDAI moderate-high subgroup
had the highest Nail PsO VAS with a median score of 17.5
(±23.4). For all patients, the highest mean HAQ of 1.06
(±0.7) was among patients in the BSA >3%/CDAI moderate-high subgroup. As BSA increased, the HAQ scores in
the moderate-high CDAI groups also increased. In those
patients with enthesitis, the highest SPARCC score of 5.3
(±3.1) was in the BSA 0%/CDAI moderate-high subgroup.
Patient-reported pain (57.1±27.6) and patient-reported
fatigue (54.0±28.2) are the highest among patients in the
BSA >3%/CDAI moderate-high subgroup. Patients with
PsA in the BSA 0%/low CDAI subgroup had the highest
mean EuroQol Group 5-Dimensional Questionnaire
scores (79.4±18.9) and a larger percentage (18.3%) of
patients reported no morning stiffness (table 2).
The relationship between degree of skin and joint
involvement
Table 3 displays the classification table of skin disease
severity (BSA, 0%, >0% to 3%, >3%) by joint involvement
(CDAI, low vs moderate-high). We observed a significant (p<0.001) modest association (Cramer’s V=0.1639)
between skin severity and joint involvement among all
patients at the time of enrolment in the study. Patients
with higher skin disease severity were over two times
more likely to have higher joint involvement (OR 2.27,
95% CI 1.71 to 3.01). Significant levels of association
between skin disease severity and joint disease activity
were also observed when stratified by therapy status at
the time of enrolment. The level of association among
patients on no DMARD therapy (Cramer’s V=0.2477)
was higher compared with patients on csDMARDs only
(Cramer’s V=0.1439) or biologics or tsDMARDs (Cramer’s V=0.1175). Specifically, patients on no DMARD
therapy at enrolment with higher skin disease severity
were 4.5 times more likely to have higher joint involvement (OR 4.52, 95% CI 2.10 to 9.73) whereas patients
on biologics or tsDMARDs at enrolment with higher
3
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2.0 (1.0, 3.0)

2.4±2.0

39 (17.2)

227

4.0 (2.0, 7.0)

4.4±2.8

227
79 (34.9)

M/H

Disease characteristics and patient-reported outcomes of all patients with PsA at time of enrolment

Enthesitis, n
n (%) with SPARCC
score >0

Table 2

14.4±14.8
9.0 (6.0, 16.0)

256

11 (4.3)

75 (29.4)

101 (39.6)

61 (23.9)

7 (2.8)

255

102 (42.9)

238

1.0 (1.0, 1.0)

1.1±0.4

8 (3.1)

256

3.5 (2.0, 6.0)

3.9±2.5

256
18 (7.0)

Low

>3%

16.2±16.6
10.0 (5.0, 18.0)

245

20 (8.3)

86 (35.7)

92 (38.2)

42 (17.4)

1 (0.4)

241

6 (2.7)

221

2.0 (2.0, 4.0)

2.7±1.8

49 (20.0)

245

4.0 (2.0, 7.0)

4.8±3.8

245
79 (32.2)

M/H

Continued

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

0.018

<0.001

0.0003

<0.001

P value
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0%

66 (25.6)
9.9±10.3

5.0 (3.0, 15.0)

255

31.4±27.2

8.5 (3.5, 14.0)

856

2.6±1.1

2.4 (1.8, 3.3)

856

496 (57.9)

260 (30.4)

100 (11.7)

677 (43.9)

1448

0.61±0.6

0.38 (0.0, 1.0)

1438

37.6±29.3

30.0 (10.0, 65.0)

1516

72.3±21.1

80.0 (60.0, 90.0)

1517

40.2±29.1

DAS28-CRP, n

 Mean (SD)

 Median (IQR)

DAS28-CRP, n

 Low, n (% of N)

 Moderate, n (%
of N)

 High, n (% of N)

Nail involvement, n
(%)

Nail PsO VAS (among 16.2±21.6
those with nail
involvement) (0–100):
mean (SD)

8.0 (4.0, 20.0)

 Median (IQR)

 Median (IQR)

HAQ (0–3), n
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 Mean (SD)

 Median (IQR)

Patient pain VAS
(0–100), n

 Mean (SD)

 Median (IQR)

EQ5D (0–1), n

 Mean (SD)

 Median (IQR)

Patient-reported
fatigue
(0–100), n
 Mean (SD)

85.0 (73.0, 92.0)

79.4±18.9

254

20.0 (5.0, 43.0)

26.7±26.0

247

0.13 (0.0, 0.6)

0.38±0.5

248

0 (0.0)

9 (5.6)

156 (94.6)

165

1.8 (1.3, 2.3)

1.8±0.6

165

4.4 (1.7, 8.0)

4.7±3.3

258

10.4±9.3

Low

1542

All patients

45.2±29.4

107

70.0 (50.0, 80.0)

64.3±23.8

105

48.0 (17.5, 70.0)

45.9±28.9

104

0.75 (0.3, 1.5)

0.88±0.7

105

5.0 (3.0, 15.0)

19.0±50.1

36 (33.0)

18 (24.7)

42 (57.5)

13 (17.8)

73

3.4 (3.0, 4.1)

3.5±0.9

73

15.5 (12.0, 21.0)

18.6±8.9

109

M/H

33.3±27.1

438

80.0 (70.0, 90.0)

77.9±17.5

440

20.0 (5.0, 50.0)

28.1±25.9

418

0.25 (0.0, 0.6)

0.40±0.5

420

5.0 (3.0, 13.0)

10.7±13.1

174 (38.9)

0 (0.0)

37 (16.1)

193 (83.9)

230

2.0 (1.6, 2.5)

2.0±0.6

230

4.8 (2.0, 8.0)

5.0±3.2

447

Low

>0% to 3%

Patients with PsA categorised by skin and joint activity

 Mean (SD)

Continued

CDAI, n

Table 2

49.7±27.8

223

70.0 (50.0, 81.0)

66.5±20.7

225

50.0 (30.0, 71.5)

50.0±26.6

208

0.88 (0.4, 1.4)

0.87±0.7

209

7.0 (4.0, 20.0)

13.5±14.2

115 (50.7)

22 (27.1)

78 (63.9)

11 (9.0)

122

3.5 (3.1, 4.1)

3.7±0.9

122

16.0 (12.5, 22.0)

18.3±8.2

227

M/H

37.4±29.1

250

80.0 (70.0, 90.0)

76.9±16.9

253

25.0 (10.0, 50.0)

32.7±28.2

239

0.25 (0.0, 0.8)

0.45±0.5

241

7.0 (4.0, 21.0)

16.6±20.0

127 (49.6)

0 (0.00)

18 (13.3)

117 (86.7)

135

2.0 (1.6, 2.4)

2.0±0.6

135

5.5 (3.0, 8.0)

5.4±3.0

256

Low

>3%

54.0±28.2

244

60.0 (40.0, 80.0)

58.8±23.4

239

60.0 (35.0, 80.0)

57.1±27.6

222

1.00 (0.5, 1.5)

1.06±0.7

225

20.0 (5.0, 40.0)

25.8±24.3

159 (64.9)

49 (37.4)

76 (58.0)

6 (4.6)

131

3.8 (3.1, 4.4)

3.9±0.9

131

17.7 (13.5, 24.5)

20.5±10.0

245

M/H

Continued

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

P value

Psoriatic arthritis
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P value represents comparisons between CDAI/BSA subgroups and were analysed using χ tests, Fisher’s exact tests, t-tests or Wilcoxon-Mann-Whitney tests, as appropriate. Skin severity
by levels of BSA: 0%, >0% to 3% and >3%; joint activity by levels of CDAI: low and M/H.
BSA, body surface area; CDAI, Clinical Disease Activity Index; DAS28-CRP, Disease Activity Score 28-joint count C-reactive protein; EQ5D, EuroQol Group 5-Dimensional Questionnaire; HAQ,
Health Assessment Questionnaire; MDA, mild disease activity; M/H, moderate/high; PsA, psoriatic arthritis; SPARCC, Spondyloarthritis Research Consortium of Canada; VAS, visual analogue
scale.

5 (4.8)
172 (11.6)
 0 hour, n (%)

46 (18.3)

1489
Morning stiffness, n

251

104

2

67 (15.6)

13 (5.9)

32 (13.3)

9 (3.7)

<0.001
242
241
222
429

60.0
(31.0, 75.0)
30.0
(10.0, 63.0)
50.0
(25.0, 75.0)
45.0
(20.0, 70.0)
25.0
(8.0, 55.0)
40.0
(12.0, 65.0)
 Median (IQR)

M/H
Low
All patients

Continued
Table 2
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25.0
(10.0, 55.0)

Low
Low

>0% to 3%
0%

Patients with PsA categorised by skin and joint activity

M/H

>3%

M/H

P value

RMD Open
skin disease severity were 1.7 times more likely to have
higher joint involvement (OR 1.70, 95% CI 1.15 to
2.52).
We observed a significant linear relationship between
CDAI and BSA (linear regression of CDAI onto BSA
is CDAI=9.48+0.16*BSA (95% CI 0.12 to 0.20 for BSA
coefficient). When we evaluated the linear relationship of CDAI and BSA accounting for a priori selected
factors as potential effect modifiers, we observed significant interactions (evidence of effect modification) that
showed this relationship was modified when accounting
for other factors. Figure 1 provides a visual representation of the effect modification between CDAI and BSA
by age, gender, work status, insurance, current therapy at
enrolment and levels of HAQ, Nail VAS, MDA, dactylitis
total, patient-reported pain and patient-reported fatigue.
The red vertical line (y=0.16) represents the 0.16 unit
increase in CDAI for every unit increase in BSA (from
the linear regression of CDAI onto BSA). Deviations
from this vertical line indicate how different levels of
the identified factors modify the association between
CDAI and BSA such that a stronger positive association
is observed (point estimate of slope coefficient for BSA
within the subgroup defined by covariate >0.16), weaker
positive association (point estimate of slope coefficient
for BSA within the subgroup defined by covariate <0.16)
or negative association (point estimate of slope coefficient for BSA within the subgroup defined by covariate
<0). The blue dotted vertical line (y=0) represents no
association.
We observed a weaker relationship between CDAI
(point estimate <0.16) and BSA when a patient appeared
to have their disease under control. These patients were
on some type of biologic or tsDMARD therapy, either
younger (18–30 years) or older (>50 years), were in
MDA, had no nail involvement (Nail VAS=0) or did not
have dactylitis. There was an inverse relationship (point
estimate of slope coefficient for BSA within the subgroup
<0) between CDAI and BSA among patients with lowest
reported pain (0–20) and fatigue (0–20), or had low
levels of HAQ; however, the strength of the positive
relationship between CDAI and BSA increased as pain,
fatigue and HAQ levels increased, respectively. A weaker
relationship (point estimate of slope coefficient for BSA
within the subgroup <0.16) between CDAI and BSA was
observed in males compared with females. A stronger
relationship (point estimate of slope coefficient for BSA
within the subgroup >0.16) was found among patients on
Other (Medicare or Medicaid) or no insurance compared
with patients on some type of private insurance (with or
without Medicare or Medicaid). When we considered
work status, we observed that for every unit increase in
BSA, CDAI had, on average, a unit increase of >0.16 for
students and those patients with PsA who work at home
or were disabled, while the mean unit increase of CDAI
was <0.16 for retirees.
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Table 3 The classification of skin disease severity (0%, >0% to 3%, >3%) by joint involvement (low vs moderate-high)
BSA
0%

>0% to 3%

>3%

Total

 Low

258

447

256

 Moderate/high

109

227

245

581

 Total

367

674

501

1542

 OR (95% CI)

Reference

P value

Cramer’s V

<0.001

0.1639

<0.001

0.2477

0.012

0.1439

0.004

0.1175

All patients
 CDAI

1.20 (0.91, 1.58)

961

2.27 (1.71, 3.01)

No DMARD therapy at enrolment
 CDAI
 Low

29

54

36

119

 Moderate/high

13

61

73

147

 Total

42

115

109

266

 OR (95% CI)

Reference

2.52 (1.19, 5.33)

4.52 (2.10, 9.73)

csDMARDs only at enrolment
 CDAI
 Low

60

 Moderate/high

30

 Total

90

 OR (95% CI)

Reference

134

71

265

68

67

165

202

138

430

1.01 (0.60, 1.72)

1.89 (1.09, 3.27)

Biologic or tsDMARDs
at enrolment
 CDAI
 Low

156

 Moderate/high

60

 Total

216

 OR (95% CI)

Reference

240

145

541

92

95

247

332

240

788

1.00 (0.68, 1.46)

1.70 (1.15, 2.52)

Drug therapy was missing for 58 patients. P value for χ2 test of association.
BSA, body surface area; CDAI, Clinical Disease Activity Index; DMARD, disease-modifying antirheumatic drug; OR, odds ratio; csDMARD, conventional
synthetic DMARD; tsDMARD, targeted synthetic DMARD.

Discussion
Our objective was to compare patient characteristics at
enrolment among patient groups stratified by degree of
skin and joint involvement and to evaluate the relationship between degree of skin and joint involvement in
patients with PsA. Our study found substantial variation
of skin and joint involvement in this cohort of patients
with PsA, with some experiencing more articular versus
skin disease and vice versa. Current therapy at enrolment
was also significantly different across the skin and joint
subgroups. It is important to note that most patients in
the BSA >3%/CDAI moderate-high subgroup had worse
clinical and patient-reported outcomes. Moreover, those
patients in the BSA 0%/CDAI low subgroup reported
the highest use of any drug therapy with 63.7% using
biologics/tsDMARD. This may speak to the effectiveness
of such therapies.
We also observed a statistically significant association
between skin disease severity and joint involvement
among all patients at the time of enrolment in the study.
Furthermore, when we evaluated the linear relationship
of CDAI and BSA, we found that some factors (ie, age,
Mease PJ, et al. RMD Open 2019;5:e000867. doi:10.1136/rmdopen-2018-000867

gender, insurance, work status, current therapy, HAQ,
Nail VAS, MDA, dactylitis count, patient-reported pain
and patient-reported fatigue) modified this relationship. In evaluating the association between CDAI and
BSA (categorised by severity level), we observed that the
association was strongest among patients on no therapy,
followed by patients on csDMARD therapy, versus
biologic or tsDMARD therapy. However, when evaluating
the linear association between CDAI and BSA (in their
continuous form), the linear association was strongest
within the csDMARD therapy group while the association within the no therapy group is lower compared with
the csDMARD group. We account for this difference
due to the nature of the analysis (linear association of
two continuous vs association between two categorical
variables). In the evaluation of the linear association, the
magnitude of the CDAI and BSA values (especially those
in higher levels of activity) will affect the estimate of the
association, whereas the effects of these larger in magnitude values are tempered when categorised into a high
severity group.
9
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Figure 1 A display of the interactions of selected variables in the evaluation of the relationship between Clinical Disease
Activity Index (CDAI) and body surface area (BSA). A display of the effect modifications by (A) age, (B) gender, (C) insurance,
(D) work status, (E) current therapy, (F) HAQ, (G) Nail VAS, (H) MDA, (I) dactylitis total, (J) patient-reported pain and (K) patientreported fatigue on the linear relationship between CDAI and BSA. Closed circles represent point estimates; horizontal bars
represent 95% confidence limits of average unit increase in CDAI for every 1 unit increase in BSA, stratified by level of each
factor (ie, beta coefficients from the regression of CDAI on BSA including factor involved in the interaction). Red vertical line
(y=0.16) represents the average increase in CDAI (0.16 increase) for every 1 unit increase in BSA (main effect from regression
of CDAI onto BSA not accounting for other factors). The blue dotted vertical line (y=0) represents no association. csDMARD,
conventional synthetic disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; MDA, minimal disease
activity; tsDMARD, targeted synthetic DMARD; VAS, visual analogue scale; WFH, work from home.

Our study found a statistically significant association
between joint disease activity and skin disease severity.
Specifically, patients with higher skin disease severity
(BSA >3%) were two times more likely to have higher
joint involvement compared with those with a BSA=0%.
These findings underscore that skin disease severity and
joint disease activity are related and addressing both
manifestations is essential in caring for patients with PsA.
Our findings of an increased likelihood of higher joint
involvement with high skin severity suggest the need for
rheumatologists and dermatologists to approach PsA
patient care comprehensively. The relationship between
skin and joint severity identified in our study indicates that
in those patients who have a positive articular response to
therapy, rheumatologists need to assess whether there is
increasing skin involvement to ensure adequate control
of both joint and skin symptoms. Likewise, when skin
disease is well managed by dermatologists, but joint
disease symptoms are persistent, rheumatologic consultation should be pursued. Although previous studies have
reported an association only between joint activity and
nail involvement,9 10 our study further showed the association between skin disease severity and joint disease
activity was stronger in certain patient subgroups, namely
those who were not in MDA, with higher Nail VAS severity,
in patients who worked from home or were students,
and who had higher HAQ and other patient-reported
outcome scores. Because of the exploratory nature of
our study, more investigation is needed to confirm these
observations.
10

Some limitations should be noted. In this study, we
used CDAI (based on 28 tender and swollen joint counts)
to define joint disease activity. Although initially derived
for rheumatoid arthritis, CDAI has been used to measure
joint activity in patients with PsA. However, a limitation of using CDAI is that it does not capture articular
involvement of feet and ankle which is frequent in PsA.
The Disease Activity in Psoriatic Arthritis (DAPSA) score
includes 66/68 joint counts, C-reactive protein (CRP) as
well as patient pain assessment. By using CDAI instead of
DAPSA, we were able to achieve a larger sample size since
CRP is not a required reporting measure in the Corrona
Registry and not available for all patients. The cDAPSA
score (DAPSA with the removal of CRP) includes patient
pain assessment, and if we used cDAPSA, another consideration, we could not have evaluated the modification of
the association between joint activity and skin severity by
patient pain, a goal of our study. Moreover, we evaluated
the correlation between CDAI and cDAPSA and observed
a high correlation (0.78) between these two disease activity
measures in our study. Misclassification due to recall bias
is a potential limitation since the registry is not based on
an inception cohort and patients could enter the study at
any time during the course of their disease. The registry
data are from a US-based registry, and the results may
not be generalisable to populations residing outside the
USA. In our study, the majority of patients (94.4%) were
white, and thus the results may not be applicable to other
racial backgrounds. However, the strengths of this study
include the ability to identify a sufficiently large cohort
of patients with PsA to characterise the relationship
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between skin disease severity and joint disease activity, as
well as to identify patient characteristics that modify that
relationship.
Our findings demonstrate that skin disease severity is
modestly correlated with joint disease activity, the relationship is affected by several patient and disease factors
and those patients with higher skin disease severity are
two times more likely to have higher joint involvement.
Understanding the association between skin and joint
involvement among patients with PsA emphasises the
need for providers (specifically rheumatologists and
dermatologists) to consider both skin disease severity and
joint disease activity in the treatment of these patients.
Further investigation of the association will help define
gaps in current therapy regimens, such as an inherent
tendency to focus on just one of the clinical domains
of the disease (ie, skin or joint disease), not both; and
address the clinical inertia by both providers and patients
as it relates to the level of baseline expectations and to
the satisfaction with treatment. Studying these differences will help us understand to what extent in the real
world skin severity and joint activity correlate.
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